WASHINGTON — Specialty pharmacies and online companies that have been selling off-brand copies of two blockbuster drugs for obesity and diabetes will need to phase out their versions next year under a federal decision issued Thursday. With demand for GLP-1 drugs booming, compounding pharmacies and telehealth companies like Hims and Ro have jumped into the market, selling cheaper versions online. …
Sign up to our free Living Well email for advice on living a happier, healthier and longer life Live your life healthier and happier with our free weekly Living Well newsletter Live your life healthier and happier with our free weekly Living Well newsletter SIGN UP I would like to be emailed about offers, events and updates from The Independent. …
As weight-loss hopefuls struggle to get name-brand Ozempic, many are turning to a booming, less regulated secondary market for compounded versions of the blockbuster drug. “We urge patients to be vigilant,” said a spokesperson for the FDA, which has issued several alerts and letters recently about concerns related to compounded semaglutide. — Food and Drug Administration The agency has issued …
Pfizer shares sank Friday when the drugmaker said it would abandon a twice-daily obesity treatment after more than half the patients in a clinical trial stopped taking it. Pfizer said it saw patient discontinuation rates topping 50% across all doses in a mid-stage study of twice-daily danuglipron. By comparison, obese patients without diabetes lost about 18% of their weight compared …
